Table 1.
Demographic and disease-related features of the patients in this study.
Figure 1.
Angiopoietin-2 (Ang-2) levels at different levels of disease activity in ANCA-associated vasculitis.
A. Serum levels in individual patients in the RAVE trial before (Screening) and after (Month 6) treatment, stratified by whether patients were in remission (left panel) or had recurrent disease (right panel) at month 6. B. Plot of serum Ang-2 versus BVAS/WG score in individual subjects in RAVE at screening. Each patient had severe disease and therefore a BVAS/WG score of at least 3. C. Plot of plasma Ang-2 versus two measures of disease activity in the VCRC longitudinal study: Physician Global Assessment (PGA, left panel) and BVAS/WG score (right panel). Note that patients in remission (PGA = 0 and BVAS/WG = 0) are included, and that Ang-2 levels are lower in plasma than in serum.
Table 2.
Ang-2 levels in patients with severe active ANCA-associated vasculitis and in the same patients after treatment in the RAVE trial.
Figure 2.
Plots of angiopoietin-2 (Ang-2) levels versus markers of systemic inflammation.
A. Serum Ang-2 versus ESR (left panel) and CRP (right panel) in the RAVE trial. Values at screening, when each patient had severe disease (BVAS/WG≥3), are shown. B. Plasma Ang-2 versus ESR (left panel) and CRP (right panel) in the VCRC longitudinal study. Note that patients in remission (BVAS/WG = 0) are included, and that Ang-2 levels are lower in plasma than in serum.
Table 3.
Ang-2 levels in clinical subgroups of active ANCA-associated vasculitis in the RAVE trial.
Figure 3.
Plots of serum angiopoietin-2 (Ang-2) levels versus GFR (top panels) or age (bottom panels).
Samples from subjects in RAVE were assayed at times of active AAV (screening, left panels) and remission 6 months after starting treatment (right panels).
Table 4.
Effects of treatment or covariates on Ang-2 levels in the RAVE trial.
Table 5.
Lack of association of Ang-2 levels during active AAV with response to treatment in the RAVE trial.
Table 6.
Lack of association of Ang-2 level during remission (and off prednisone) with time to flare of ANCA-associated vasculitis (AAV) in the RAVE trial.